CClinicalTrials.gg
CompletedNCT00903344Updated Aug 18, 2014Results posted

Impact of Vitamin D Supplementation on Lactation Associated Bone Loss

An interventional study of Vitamin D3 and Multivitamin in Osteoporosis, sponsored by Leigh Eck, MD. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-18.

Sponsored by Leigh Eck, MD · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Studies have shown that lactation is associated with a loss of bone density from four to seven percent at the spine and hip among women who lactate for six months. Decline in bone density with lactation occurs rapidly. Although bone density increases after weaning, there is controversy on whether or not it is completely restored. Epidemiological studies find no significant negative impact of lactation on bone mass or fractures, and in fact there is evidence that lactation has a positive effect on bone mass. We think that interventions that attenuate this physiologic loss of bone that is associated with lactation and accelerate restoration of bone mass after weaning may result in improved long term bone mass and diminished fracture risk.

Read the detailed description

Adequate vitamin D stores are necessary for skeletal health. Vitamin D deficiency is pronounced in women of child bearing age as well as pregnant women in the United States. This study will provide important information about whether vitamin D supplementation may positively impact the normal physiologic loss of bone mass that is observed during lactation.

Recruitment will begin while subjects are pregnant in order to expedite entry into the study in the immediate post-partum period. If subjects are deemed eligible during pregnancy, contact information to include name, address, expected delivery date and two contact phone numbers will be obtained. Subjects will be contacted two weeks prior to expected delivery date and then again at expected delivery date. Subjects will be followed for a total of 18 months.

02

Conditions studied

  • Osteoporosis

Browse trials for

03

In context

Osteoporosis

1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.

This study's enrollment of 22 is below the median of 95 across 1,133 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

This is the only study on the registry with Leigh Eck, MD as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Fully lactating mothers age 18 and up
  • Within 1 month after delivery
  • Plan to breast feed for at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Known metabolic bone disease
  • Chronic renal insufficiency
  • Chronic corticosteroid use
  • Eating disorder
  • Estrogen containing hormonal contraception use
  • Daily use of >400IU Vitamin D supplementation
  • Delivery of Multiples
  • Delivery of a singleton with a birth weight of \<2500 grams
  • Preterm delivery of baby
  • History of kidney stones
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Vitamin D

    4000IU Vitamin D3 in tablet taken daily with multivitamin

    Drug: Vitamin D3

  • Active comparator
    Multivitamin

    Multivitamin with 400IU vitamin D tablet

    Dietary Supplement: Multivitamin

Interventions

  • DrugVitamin D3

    4000IU vitamin D3 tablet taken daily

  • Dietary supplementMultivitamin

    Multivitamin containing 400IU vitamin D in tablet taken daily

06

What researchers measure

Primary outcomes

  1. Change in Bone Mineral Density (BMD) in HIP at 6 Months

    Time frame: Change from Baseline to 6 months

Secondary outcomes

  1. Change in 25-hyroxyvitamin D Levels at 3 Months

    Difference in means between visits

    Time frame: Change from Baseline to 3 Months

  2. Change in 25-hyroxyvitamin D Levels at 6 Months

    Time frame: Change from Baseline to 6 Months

  3. Change in Bone Mineral Density (BMD) at HIP at 3 Months

    Time frame: Change from Baseline to 3 months

  4. Change in Bone Mineral Denisty (BMD) in SPINE at 3 Months

    difference in mean

    Time frame: Change from Baseline to 3 Months

  5. Change in Bone Mineral Denisty (BMD) in SPINE at 6 Months

    difference in the mean

    Time frame: Change from Baseline to 6 Months

07

Results

Posted Aug 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneVitamin D - ExperimentalMultivitamin - Active Comparator
Started1210
3 month visit1010
6 month visit910
Completed77
Not completed53
Withdrew: Pregnancy23
Withdrew: Lost to follow-up30

Outcome measures

PrimaryChange in Bone Mineral Density (BMD) in HIP at 6 Months
Time frame:
Change from Baseline to 6 months
Reported as:
Mean · grams/cm^2
Change in Bone Mineral Density (BMD) in HIP at 6 Months
grams/cm^2Vitamin D - ExperimentalMultivitamin - Active Comparator
Change in Bone Mineral Density (BMD) in HIP at 6 Months-0.041 ± 0.0140.011 ± 0.122
SecondaryChange in 25-hyroxyvitamin D Levels at 3 Months

Difference in means between visits

Time frame:
Change from Baseline to 3 Months
Reported as:
Mean · ng/ml
Change in 25-hyroxyvitamin D Levels at 3 Months
ng/mlVitamin D - ExperimentalMultivitamin - Active Comparator
Change in 25-hyroxyvitamin D Levels at 3 Months2.600 ± 7.230-5.850 ± 7.713
SecondaryChange in 25-hyroxyvitamin D Levels at 6 Months
Time frame:
Change from Baseline to 6 Months
Reported as:
Mean · ng/ml
Change in 25-hyroxyvitamin D Levels at 6 Months
ng/mlVitamin D - ExperimentalMultivitamin - Active Comparator
Change in 25-hyroxyvitamin D Levels at 6 Months1.889 ± 7.865-3.200 ± 13.774
SecondaryChange in Bone Mineral Density (BMD) at HIP at 3 Months
Time frame:
Change from Baseline to 3 months
Reported as:
Mean · grams/cm^2
Change in Bone Mineral Density (BMD) at HIP at 3 Months
grams/cm^2Vitamin D - ExperimentalMultivitamin - Active Comparator
Change in Bone Mineral Density (BMD) at HIP at 3 Months-0.017 ± 0.009-0.016 ± 0.022
SecondaryChange in Bone Mineral Denisty (BMD) in SPINE at 3 Months

difference in mean

Time frame:
Change from Baseline to 3 Months
Reported as:
Mean · grams/cm^2
Change in Bone Mineral Denisty (BMD) in SPINE at 3 Months
grams/cm^2Vitamin D - ExperimentalMultivitamin - Active Comparator
Change in Bone Mineral Denisty (BMD) in SPINE at 3 Months-0.025 ± 0.071-0.025 ± 0.030
SecondaryChange in Bone Mineral Denisty (BMD) in SPINE at 6 Months

difference in the mean

Time frame:
Change from Baseline to 6 Months
Reported as:
Mean · grams/cm^2
Change in Bone Mineral Denisty (BMD) in SPINE at 6 Months
grams/cm^2Vitamin D - ExperimentalMultivitamin - Active Comparator
Change in Bone Mineral Denisty (BMD) in SPINE at 6 Months-0.060 ± 0.036-0.109 ± 0.115

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vitamin D - Experimental—0/12 (0%)1/12 (8.3%)
Multivitamin - Active Comparator—0/10 (0%)0/10 (0%)
Most frequent other events
Most frequent other events
EventVitamin D - ExperimentalMultivitamin - Active Comparator
ConstipationGastrointestinal disorders1/120/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vitamin D - ExperimentalMultivitamin - Active ComparatorTotal
Mean29 ± 632 ± 330 ± 4.64
Sex: Female, Male
Sex: Female, Male(Participants)Vitamin D - ExperimentalMultivitamin - Active ComparatorTotal
Female121022
Male000
Region of Enrollment
Region of Enrollment(participants)Vitamin D - ExperimentalMultivitamin - Active ComparatorTotal
United States121022
08

Study locations

1 site
  • University of Kansas Medical Center
    Kansas City, Missouri 66160, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00903344
Lead sponsor
Leigh Eck, MD
Collaborators
Bio-Tech Pharmacal, Inc.
Responsible party
Leigh Eck, MD (Assistant Professor, University of Kansas Medical Center) — Sponsor-investigator
First posted
May 18, 2009
Start date
Dec 2009
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Aug 18, 2014
Last update
Aug 18, 2014

Study contacts

Leigh Eck, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion